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Biochemical markers in the management 
of pulmonary hypertension
John-David Aubert
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Pulmonary arterial hypertension (PAH) is a se-
vere disease usually diagnosed by echocardiogra-
phy and further confirmed by right heart catheter-
isation. Follow-up under treatment consists in as-
sessment of clinical signs, various types of exercise
testing and repeated echocardiograms. Several
molecules which can be measured in the blood or
sometimes in other biological fluids are known to
be elevated in PAH. The most extensively studied
are members of the family of natriuretic peptides,
uric acid, and products generated by nitric oxide
activity. Due to the low prevalence of PAH and
their suboptimal specificity, these potential mark-
ers are generally of modest positive predictive
value which precludes their use as screening tools.
However, some of them correlate significantly
with prognosis, and thus, in conjunction with clas-
sical clinical and paraclinical parameters, they may
be a further aid to clinical decision-making for the
specialist dealing with PAH patients.
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Pulmonary hypertension is a disease which
dramatically limits exercise capacity and seriously
reduces life expectancy. The causes of or condi-
tions associated with pulmonary arterial hyperten-
sion (PAH) are well documented and were recently
reclassified at the 3rd World Symposium on PAH
(Venice 2003, table 1) [1]. The symptoms and clin-
ical signs of early PAH are notoriously vague and
unspecific, and hence PAH is often misdiagnosed
for other conditions such as asthma, cardiac is-
chaemic disease, muscular deconditioning or even
depression. Most often the diagnosis is established
by transthoracic echocardiography, on the basis of
the velocity of the regurgitant tricuspid jet. Com-
monly used definitions of PH are pulmonary ar-
tery systolic pressure (PASP) >35 mm Hg or mean
>25 mm Hg at rest, or mean >30 mm Hg at exer-
cise [2]. In some cases, such as emphysema or mild
PAH, the tricuspid jet cannot be measured and the
diagnosis of PAH may be missed. Echocardio-
graphic findings should be confirmed by right
heart catheterisation with invasive haemodynamic
measurements and acute vasoreactivity testing [3]. 
The follow-up of patients with PAH is based
on history and clinical evaluation, assessment of 
exercise capacity according to the NYHA/WHO
scale and exercise testing such as the 6 minutes
walking test (6MWT) [4]. This latter test has been
shown to correlate well with haemodynamic mea-
surements and with survival, and it has thus been a
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Abbreviations:
PAH Pulmonary arterial hypertension
6MWT 6 minutes walk test
BNP Brain natriuretic peptide
ANP Atrial natriuretic peptide
CTnT Cardiac troponin T
ET-1 Endothelin-1
NO Nitric oxide
CGMP Cyclic guanosine monophosphate
ACE Angiotensin-converting enzyme
Introduction
major endpoint in recent clinical studies. In expe-
rienced hands echocardiography can also be a valu-
able tool for evaluation of the long term response
to drug therapy [5].
Until now blood tests have not been used on a
regular basis either for screening or follow-up
under treatment. Several biological substances are
known to be elevated in PAH and have been mea-
sured in peripheral blood (table 2). We briefly
review the most relevant biomarkers in PAH and
analyse their usefulness in the clinical setting. 
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1. Pulmonary arterial hypertension (PAH)
1.1. Idiopathic (IPAH)
1.2. Familial (FPAH)
1.3. Associated with (APAH):
1.3.1. Collagen vascular disease
1.3.2. Congenital systemic-to-pulmonary shunts
1.3.3. Portal hypertension
1.3.4. HIV infection
1.3.5. Drugs and toxins
1.3.6. Other 
1.4. Associated with significant venous or capillary involvement
1.4.1. Pulmonary veno-occlusive disease (PVOD)
1.4.2. Pulmonary capillary haemangiomatosis (PCH)
1.5. Persistent pulmonary hypertension of the newborn
2. Pulmonary hypertension with left heart disease
2.1. Left-sided atrial or ventricular heart disease
2.2. Left-sided valvular heart disease
3. Pulmonary hypertension associated with lung diseases and/or hypoxaemia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Sleep-disordered breathing
3.4. Alveolar hypoventilation disorders
3.5. Chronic exposure to high altitude
3.6. Developmental abnormalities
4. Pulmonary hypertension due to chronic thrombotic and/or embolic disease
4.1. Thromboembolic obstruction of proximal pulmonary arteries
4.2. Thromboembolic obstruction of distal pulmonary arteries
4.3. Non-thrombotic pulmonary embolism 
5. Miscellaneous Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels 
Markers Main site of synthesis Selected clinical 
human studies
Brain natriuretic peptide (BNP) myocytes [6, 8]
Pro-brain natriuretic peptide (ProBNP) myocytes [9, 11]
Troponin T myocytes [14]
Uric acid ubiquitous [15, 44]
Endothelin-1 endothelium [19–22, 47]
Serotonin platelets (storage) [29]
Angiotensinogen/angiotensin I–III, ACE vascular wall [30, 48]
NO endothelium [28]
cGMP vascular wall: smooth muscle [24, 49]
D-dimers from fibrin; ubiquitous (platelets) [41]
Table 1
Clinical Classification
of Pulmonary Hyper-
tension (Venice
2003), see reference
[1].
Table 2
Potential biochemical
markers in pulmo-
nary hypertension.
Natriuretic peptides
Atrial natriuretic (ANP) and brain natriuretic
peptide (BNP) represent the major hormones of
the natriuretic peptide system. These peptide hor-
mones are synthesised and excreted mainly by the
cardiac myocytes from both the right and left ven-
tricles. BNP is first synthesised as a precursor,
preproBNP, which is enzymatically cleaved to
form proBNP. ProBNP is further processed into
mature BNP and an N-terminal fragment, NT-
proBNP, which is biologically inactive (figure 1).
Mature BNP has a short half-life of about 22 min
in plasma, whereas NT-proBNP has a half-life of
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2 hours. This latter peptide is cleared through the
kidneys and hence its blood level rises in a signifi-
cant way in the event of altered renal function,
which is not the case of BNP. 
BNP has been shown to be elevated in various
form of PAH including idiopathic PAH [6], PAH
associated with interstitial lung disease [7], with
congenital systemic-to-pulmonary shunts [8], with
chronic obstructive pulmonary disease [9], and in
chronic thromboembolic pulmonary hypertension
[10]. Thus, whereas BNP levels are not discrimi-
native for the aetiology of PAH, they correlate with
other classical endpoints such as the NYHA func-
tional class, the 6MWT and haemodynamic pa-
rameters [6].
Since NT-proBNP shares the same intracellu-
lar precursor with BNP, it comes as no surprise that
similar findings have been published with this pep-
tide. In particular, NT-proBNP is elevated in PAH
associated with systemic sclerosis [11], and in idio-
pathic PAH [9]. In this latter study, various termi-
nal chronic pulmonary diseases, even with mild to
moderate PAH, were not associated with elevated
NT-proBNP. 
ANP is also elevated in idiopathic and other
forms of PAH. Wiedemann and colleagues ob-
served a tenfold increase in 18 patients, including
11 with idiopathic PAH. However, ANP does not
appear to be elevated in moderate PAH associated
with various conditions [12].
A large body of evidence shows that in normal
individuals natriuretic peptides are secreted from
the atrium, whereas in the case of left or right ven-
tricular hypertrophy or failure, both ventricles
could be the major sources of synthesis. It is there-
fore obvious that in any case where cardiopathy af-
fecting the left heart coexists with PAH, the diag-
nostic or prognostic value of natriuretic peptide
levels are meaningless. Other conditions such as
acute respiratory distress syndrome are also known
to raise natriuretic peptide levels [13].
preproBNP134 aa
proBNP 108 aaSignal Peptide 
26 aa
NT-proBNP 76 aa BNP 32 aa
Biologically inactive
Half -life 2 hours
Renal Clearance
Biologically active
Half -life 22 min.
Clearance through 
neutral endopeptidase
Cardiac
Myocyte
Figure 1
Intra- and extracellu-
lar processing of
brain natriuretic
peptide.
Troponin
Cardiac troponin T (cTnT) is a specific
marker of cardiomyocyte injury which is de-
tectable when either the left or the right ventricle
is injured. Torbicki and colleagues have recently
evaluated the prognostic value of this biochemical
parameter in 56 patients with severe PAH [14].
Significant levels of cTnT were detected in 8 pa-
tients. Despite similar cardiac haemodynamics,
these patients had significantly worse survival than
the remaining 48. Indeed, cTnT was found by
multivariate analysis to be an independent risk fac-
tor for mortality in a 24-month period, together
with the 6MWT and pulmonary vascular resis-
tance. It is therefore likely that cTnT is a marker
of excessive stress to the right ventricle, and the au-
thors suggest that cTnT may be of use in making
therapeutic decisions such as starting intravenous
epoprostenol or putting the patient on the waiting
list for lung transplantation. Experience to date
with cTnT relies on the experience of a single cen-
tre, and therefore the data, to be fully validated,
require confirmation by publications from other
investigators.
Uric acid
Uric acid may be elevated in the blood of pa-
tients with chronic hypoxic conditions such as
heart failure or COPD. The elevation is thought
to be the consequence impaired oxidative metab-
olism of the tissue, with increased degradation of
adenine nucleotides such as ATP. Uric acid is
known to be a risk factor for long term mortality
in heart failure. Uric acid has been found to be
elevated in the serum of patients with idiopathic
pulmonary hypertension, and correlates with pul-
monary vascular resistance [15]. In the light of a
study with a 31–month follow-up period in 90 pa-
tients, uric acid also appears to be an independent
risk factor for mortality [15].
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Serotonin is a vasoactive substance that is syn-
thesised in enterochromaffin intestinal cells, ac-
tively stored in platelets and cleared through the
vascular endothelium. In clinical conditions an in-
crease in plasma serotonin could be the result of
either platelet activation (as in thrombosis) or de-
fective endothelial clearance. Mean plasma sero-
tonin concentration was elevated in 16 patients
with severe idiopathic PAH compared with con-
trols and correlated with pulmonary vascular
resistance [29]. It is interesting to note that
epoprostenol treatment, a known antiaggregating
agent conventionally used for stage IV PAH, did
not modify plasma serotonin levels in PAH pa-
tients despite haemodynamic improvement.
While the exact origin of elevated plasma sero-
tonin remains unclear, this study demonstrates
that platelet activation is not involved and that de-
fective endothelial clearance is the more likely cul-
prit. Serotonin concentration cannot be used to
monitor treatment efficacy in patients with PAH
[29].
Endothelin-1
Endothelin-1 (ET-1) is a 21 aminoacid peptide
with potent vasoconstricting and remodelling
properties. Increased gene expression of this mol-
ecule has been observed in the arterial wall of
patients with idiopathic PAH [16] and synthetic
antagonists of ET receptors have proved to be ben-
eficial in various forms of PAH [17, 18]. Several re-
ports have shown elevated plasma levels for ET-1,
or its precursor Big ET-1, in PAH [19–21] and in
PAH associated with COPD [22]. However, ET-1
measurement is complicated by technical difficul-
ties: 1. the half-life of the molecule is extremely
short (merely a couple of minutes), 2. a significant
part of the plasmatic ET-1 pool is cleared through
the pulmonary vascular bed by neutral endopepti-
dase, and therefore sampling from the pulmonary
bed may differ significantly from venous periph-
eral blood, 3. ET-1 levels appear to be quite sensi-
tive to physiological or pathological factors such as
upright versus supine position, venous blood sta-
sis, systemic hypertension etc. For these reasons
plasma ET-1 is far from being a real-life ideal
marker outside the setting of carefully conducted
clinical studies.
Products of NO metabolism
Nitric oxide (NO) plays a critical role in the
regulation of pulmonary vascular resistance [23].
The endothelial isoform of NO synthase (ecNOS)
generates free NO in the nanomolar range which
acts in a paracrine way on the smooth muscle cells
to generate cyclic guanosine monophosphate
(cGMP) and eventually smooth muscle relaxation.
Theoretically a low plasma NO could be a marker
of endothelial dysfunction and possibly of PAH,
but NO itself is too labile to be measured in its
gaseous form in the blood. Plasma cGMP has been
used as a surrogate marker of ecNOS activity
through activation of guanylate cyclase, especially
in hypertension affecting the neonate [24]. It is im-
portant to bear in mind, however, that both NO
and natriuretic peptides are able to generate
cGMP, and therefore plasma cGMP levels usually
correlate with BNP or ANP levels and are elevated
in PAH [25]. cGMP can also be measured in the
urine and is elevated in PAH compared with con-
trols or patients with acute asthma [26]. It is inter-
esting to note that urinary cGMP correlates with
haemodynamics in PAH patients, especially with
cardiac index. In accordance with pathophysiolog-
ical knowledge, plasma nitrite levels were found 
to be low in patients with chronic hypoxic lung 
diseases [27]. Currently, plasma nitrite is not con-
sidered as a marker of pulmonary hypertension.
Although NO can also be measured in exhaled air
[28], endogenous production of NO by the airway
mucosa usually far exceeds the fraction diffusing
from the lung vessels, thus precluding its measure-
ment as a marker of pulmonary circulation home-
ostasis. As is the case of the natriuretic peptides,
products of NO metabolism are elevated in either
chronic or acute congestive heart failure.
Serotonin
Other endothelial markers
The expression of various endothelial markers
has been investigated in the context of PAH. An-
giotensin-converting enzyme (ACE) genotype
DD appears to be more often expressed in severe
idiopathic PAH [30, 31]. Locally, expression of im-
munoreactive ACE has been observed in plexiform
lesions, a hallmark of almost all forms of PAH [32].
Increased serum ACE activity has been measured
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Fibrinogen metabolism products
It is now well recognised that in situ microvas-
cular thombosis does occur in all form of PAH and
accelarate the progression of the disease [40]. On
the basis of these observations Shitrit and col-
leagues investigated the significance of the well
known D-dimer assay in 14 patients with idio-
pathic PAH [41]. D-dimer assay correlated with
exercise capacity assessed both by the NYHA scale
or the 6MWT, and correlated inversely with one
year survival (p = 0.004). The median value was
1085 ug/L with a range from 20–6200 ug/L. These
preliminary data obviously need confirmation in a
larger group of patients and adequate control
groups.
in patients with collagen vascular disease-associ-
ated PAH compared with unaffected patients.
However, there is a large overlap between the two
groups, suggesting that a clinically useful thresh-
old would be difficult to establish.
Abnormalities in von Willebrand factor
[33–35], plasmin-a2 inhibitor complex [36],
thrombomodulin [37], lipoprotein(a) [38], and an-
giopoietin [39] have all been described in animal
models or human PAH. However, more clinical
studies are needed to evaluate their practical use-
fulness as surrogate markers in patients with PAH.
An ideal marker should be sensitive, repro-
ducible and easy to perform. It is not sufficient for
a biological parameter to be elevated in affected
patients and to correlate more or less closely with
other clinical variables. In the case of PAH, a po-
tential application of biochemical markers may be
for screening or for clinical follow-up of treated
patients.
Potential clinical applications
Screening
PAH is too rare a disease (incidence 4/106 in-
habitants per year for idiopathic PAH) for screen-
ing to be applied to the general population [42].
However, screening could be relevant in risk
groups such as familial PAH, systemic sclerosis,
cardiac shunt or liver disease. Allanore and col-
leagues have published the results of   screening in
40 consecutive patients with limited or diffuse dis-
ease [11]. Systemic sclerosis is a disease which may
be complicated by PAH in 10–30% of cases. Using
systolic PA pressure measured by echocardiogra-
phy, the authors identified 10 patients with PAH.
The negative predictive value of a commercially
available kit for NT-proBNP determination was
quite high at 96%, meaning that when an NT-
proBNP value is below the 97th centile the proba-
bility of PAH is very low. However, the positive
predictive value was only at 69.2%, that is, the sig-
nificance of high NT-proBNP is questionable in
the context of PAH. In patients where the preva-
lence of PAH is lower, e.g. in rheumatoid arthritis
or in HIV patients, the predictive positive value
would fall still further. It must also be emphasised
that in this study of scleroderma, patients with heart
failure were carefully excluded by nuclear ven-
triculography. The cost-effectiveness of screening
is obviously unfavourable compared with echocar-
diography, which provides both diagnoses in the
same examination. It is worth recalling that
echocardiography has been shown to have 90%
sensitivity and a 75% specificity in the context of
PAH associated with systemic sclerosis [43]. To ar-
rive at a definitive assessment of a biochemical
marker as a screening tool for PAH it would be
necessary to conduct a study comparing conven-
tional echocardiography and the putative marker,
using right heart catheterisation as the gold stan-
dard. To the best of our knowledge no such study
has been yet published.
Clinical follow-up
Right heart catheterisation cannot be per-
formed repeatedly and in many cases pulmonary
systolic pressure measured by echocardiography
does not change despite obvious improvement or
deterioration of a patient’s condition. Other meth-
ods of clinical evaluation such as the 6MWT are
conventionally used for patient follow-up. Bio-
chemical markers such as BNP and proBNP [11,
44], uric acid [45], D-dimers [41] and troponin T
[14] have shown promising results in that they
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appear to correlate with survival, often independ-
ently of haemodynamics. It will be of interest to
evaluate how these markers compare with new de-
velopments in echocardiography and magnetic
resonance imaging [5, 46]. Although these positive
data need to be confirmed in larger studies, a plau-
sible case can be made that in the future such mark-
ers, used in conjunction with conventional clinical
evaluation, could be of assistance in therapeutic
decision-making such as medication change or
lung transplantation. It is however premature to
recommend their routine use in daily practice. At
present these markers are of interest to pulmonary
hypertension specialists in possibly providing
deeper insights into the  pathophysiology of the
disease.
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